Kineta announces completion of enrollment in monotherapy arm of VISTA-101
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2024
0mins
Clinical Trial Enrollment: Kineta has completed patient enrollment for the monotherapy arm of the VISTA-101 phase 1 clinical trial, testing its KVA12123 immunotherapy in advanced solid tumors without observing dose limiting toxicities or adverse events.
Combination Therapy Evaluation: The company is also enrolling patients for cohorts that will evaluate KVA12123 in combination with Merck's KEYTRUDA anti-PD-1 therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 114.700
Low
95.00
Averages
119.53
High
139.00
Current: 114.700
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Predicts 14% Upside for S&P 500
- S&P 500 Target Price: Wall Street anticipates a 14% increase in the S&P 500 over the next year, with a target price of 8,698, up from the current level of 7,615, reflecting optimism about economic recovery.
- Healthcare Sector Outlook: Analysts predict that earnings growth in the healthcare sector will slow to 3% by 2026, although it is expected to accelerate to 19% in 2027; however, the current valuation of 27 times earnings may deter investors due to perceived overvaluation.
- Communication Services ETF Performance: The Vanguard Communication Services ETF has returned 152% over the past decade (annualized at 9.6%), with major holdings like Alphabet and Meta, and is projected to see earnings growth of 28% in 2026, indicating strong growth potential.
- Investment Recommendations: Despite the positive outlook for healthcare and communication services, analysts suggest maintaining a larger allocation in S&P 500 index funds to mitigate potential market volatility and capitalize on the strong performance of technology stocks.
See More
Moderna's Biotech Progress Shows Promise
- Vaccine Development Progress: Moderna is awaiting approval for its flu vaccine after submitting regulatory applications in the U.S., Europe, Australia, and Canada, which could address the market's need for newer options, particularly for vulnerable senior populations.
- Personalized Cancer Vaccine: The mRNA-4157, developed in collaboration with Merck, has shown significant potential in reducing recurrence or death risk in advanced melanoma patients during phase 2 studies, and if approved, could generate billions in sales for Moderna.
- mRNA Platform Advantage: Moderna's mRNA vaccines can be developed faster than traditional ones, allowing for rapid responses to emerging pathogens, and its success in the COVID vaccine market sets a strong precedent for future applications across various therapeutic areas.
- Market Risks and Opportunities: Despite Moderna's market cap reaching $18 billion, it reported only $389 million in revenue for Q1, prompting investors to be cautious of potential stock volatility due to clinical or regulatory setbacks.
See More
Moderna's Optimistic Outlook Amid Strong Pipeline Progress
- Vaccine Market Potential: Moderna's mRNA-1010 flu vaccine has outperformed traditional vaccines in older adults, and if approved, it could meet the demand for more effective options, significantly enhancing the company's market share in the flu vaccine sector.
- Cancer Vaccine Development Progress: The mRNA-4157 personalized cancer vaccine, developed in collaboration with Merck, has shown significant efficacy in reducing recurrence or death risk in advanced melanoma patients during phase 2 trials, with potential sales in the billions if successfully launched.
- Market Performance and Risks: Despite a 43% stock price increase this year, Moderna's market cap has reached $18 billion, while it reported only $389 million in revenue for Q1, indicating profitability concerns; investors should be wary of potential clinical or regulatory setbacks that could lead to stock volatility.
- Innovative Platform Advantage: Moderna's mRNA platform offers rapid development capabilities, and with several products entering phase 3 trials, it is expected to generate new revenue streams; however, investors must carefully assess whether market expectations for future growth are realistic.
See More
Moderna and Merck's Cancer Vaccine Shows Significant Efficacy in Late-Stage Melanoma
- Clinical Trial Results: Moderna and Merck's experimental cancer vaccine intismeran autogene combined with Keytruda demonstrated a 49% reduction in the risk of recurrence or death and a 50% reduction in distant metastasis risk in high-risk late-stage melanoma patients, indicating the potential efficacy of this therapy.
- Long-Term Follow-Up Data: Based on a median five-year follow-up of the phase 2 KEYNOTE-942/mRNA-4157-P201, overall survival showed a positive trend, further validating the long-term efficacy and safety of the vaccine.
- Expansion Potential: Intismeran autogene, known as an mRNA individualized neoantigen therapy, is also being investigated for other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma, showcasing its broad application prospects.
- Market Impact and Outlook: This breakthrough data could enhance the market competitiveness of Moderna and Merck in the field of cancer immunotherapy, attracting more investments and accelerating the progression of subsequent clinical trials.
See More
Merck Considers COVID Drug for Ebola Treatment Amid Outbreak
- Ebola Outbreak Escalation: The outbreak in the Democratic Republic of Congo has infected approximately 1,100 people and resulted in 42 deaths, involving a rare Bundibugyo virus strain for which no approved vaccines or treatments exist.
- Drug Application Exploration: Merck is in discussions with global health authorities about using its COVID antiviral pill molnupiravir as an Ebola treatment, which, while not approved for this use, has shown some efficacy in animal studies.
- Vaccine Development Potential: The Chief Medical Officer of Merck indicated that the existing Ebola vaccine Ervebo may provide technological support for developing a new vaccine, showcasing the company's strategic flexibility in addressing the outbreak.
- Regional Concerns: With Uganda reporting 9 confirmed cases and 1 death, Merck's HIV research sites in the area highlight the company's heightened awareness of the public health crisis, reflecting its sensitivity to epidemic developments.
See More
Ivonescimab Data Enhances Market Prospects Against Keytruda
- Survival Extension: The Phase 3 Harmoni-6 study presented at ASCO demonstrated that Ivonescimab combined with chemotherapy extended median overall survival from 23.7 months to 27.9 months, with nearly 65% of patients alive after two years, significantly enhancing its market competitiveness.
- Intensifying Industry Competition: The success of Ivonescimab has heightened pressure on major pharmaceutical players like Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK), all of whom are advancing rival therapies, particularly in light of the impending patent cliff.
- FDA Review Progress: Summit Therapeutics has submitted an FDA application for Ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with a regulatory decision expected by November 14, positioning the company advantageously in the competitive landscape.
- Investor Sentiment Rebound: Retail investor sentiment for SMMT surged to an all-time high of 97/100 on Stocktwits, with message volume increasing by over 9,200%, reflecting strong market confidence in the future potential of Ivonescimab.
See More
Wall Street Predicts 14% Upside for S&P 500
- S&P 500 Target Price: Wall Street anticipates a 14% increase in the S&P 500 over the next year, with a target price of 8,698, up from the current level of 7,615, reflecting optimism about economic recovery.
- Healthcare Sector Outlook: Analysts predict that earnings growth in the healthcare sector will slow to 3% by 2026, although it is expected to accelerate to 19% in 2027; however, the current valuation of 27 times earnings may deter investors due to perceived overvaluation.
- Communication Services ETF Performance: The Vanguard Communication Services ETF has returned 152% over the past decade (annualized at 9.6%), with major holdings like Alphabet and Meta, and is projected to see earnings growth of 28% in 2026, indicating strong growth potential.
- Investment Recommendations: Despite the positive outlook for healthcare and communication services, analysts suggest maintaining a larger allocation in S&P 500 index funds to mitigate potential market volatility and capitalize on the strong performance of technology stocks.
See More
Moderna's Biotech Progress Shows Promise
- Vaccine Development Progress: Moderna is awaiting approval for its flu vaccine after submitting regulatory applications in the U.S., Europe, Australia, and Canada, which could address the market's need for newer options, particularly for vulnerable senior populations.
- Personalized Cancer Vaccine: The mRNA-4157, developed in collaboration with Merck, has shown significant potential in reducing recurrence or death risk in advanced melanoma patients during phase 2 studies, and if approved, could generate billions in sales for Moderna.
- mRNA Platform Advantage: Moderna's mRNA vaccines can be developed faster than traditional ones, allowing for rapid responses to emerging pathogens, and its success in the COVID vaccine market sets a strong precedent for future applications across various therapeutic areas.
- Market Risks and Opportunities: Despite Moderna's market cap reaching $18 billion, it reported only $389 million in revenue for Q1, prompting investors to be cautious of potential stock volatility due to clinical or regulatory setbacks.
See More
Moderna's Optimistic Outlook Amid Strong Pipeline Progress
- Vaccine Market Potential: Moderna's mRNA-1010 flu vaccine has outperformed traditional vaccines in older adults, and if approved, it could meet the demand for more effective options, significantly enhancing the company's market share in the flu vaccine sector.
- Cancer Vaccine Development Progress: The mRNA-4157 personalized cancer vaccine, developed in collaboration with Merck, has shown significant efficacy in reducing recurrence or death risk in advanced melanoma patients during phase 2 trials, with potential sales in the billions if successfully launched.
- Market Performance and Risks: Despite a 43% stock price increase this year, Moderna's market cap has reached $18 billion, while it reported only $389 million in revenue for Q1, indicating profitability concerns; investors should be wary of potential clinical or regulatory setbacks that could lead to stock volatility.
- Innovative Platform Advantage: Moderna's mRNA platform offers rapid development capabilities, and with several products entering phase 3 trials, it is expected to generate new revenue streams; however, investors must carefully assess whether market expectations for future growth are realistic.
See More
Moderna and Merck's Cancer Vaccine Shows Significant Efficacy in Late-Stage Melanoma
- Clinical Trial Results: Moderna and Merck's experimental cancer vaccine intismeran autogene combined with Keytruda demonstrated a 49% reduction in the risk of recurrence or death and a 50% reduction in distant metastasis risk in high-risk late-stage melanoma patients, indicating the potential efficacy of this therapy.
- Long-Term Follow-Up Data: Based on a median five-year follow-up of the phase 2 KEYNOTE-942/mRNA-4157-P201, overall survival showed a positive trend, further validating the long-term efficacy and safety of the vaccine.
- Expansion Potential: Intismeran autogene, known as an mRNA individualized neoantigen therapy, is also being investigated for other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma, showcasing its broad application prospects.
- Market Impact and Outlook: This breakthrough data could enhance the market competitiveness of Moderna and Merck in the field of cancer immunotherapy, attracting more investments and accelerating the progression of subsequent clinical trials.
See More
Merck Considers COVID Drug for Ebola Treatment Amid Outbreak
- Ebola Outbreak Escalation: The outbreak in the Democratic Republic of Congo has infected approximately 1,100 people and resulted in 42 deaths, involving a rare Bundibugyo virus strain for which no approved vaccines or treatments exist.
- Drug Application Exploration: Merck is in discussions with global health authorities about using its COVID antiviral pill molnupiravir as an Ebola treatment, which, while not approved for this use, has shown some efficacy in animal studies.
- Vaccine Development Potential: The Chief Medical Officer of Merck indicated that the existing Ebola vaccine Ervebo may provide technological support for developing a new vaccine, showcasing the company's strategic flexibility in addressing the outbreak.
- Regional Concerns: With Uganda reporting 9 confirmed cases and 1 death, Merck's HIV research sites in the area highlight the company's heightened awareness of the public health crisis, reflecting its sensitivity to epidemic developments.
See More
Ivonescimab Data Enhances Market Prospects Against Keytruda
- Survival Extension: The Phase 3 Harmoni-6 study presented at ASCO demonstrated that Ivonescimab combined with chemotherapy extended median overall survival from 23.7 months to 27.9 months, with nearly 65% of patients alive after two years, significantly enhancing its market competitiveness.
- Intensifying Industry Competition: The success of Ivonescimab has heightened pressure on major pharmaceutical players like Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK), all of whom are advancing rival therapies, particularly in light of the impending patent cliff.
- FDA Review Progress: Summit Therapeutics has submitted an FDA application for Ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with a regulatory decision expected by November 14, positioning the company advantageously in the competitive landscape.
- Investor Sentiment Rebound: Retail investor sentiment for SMMT surged to an all-time high of 97/100 on Stocktwits, with message volume increasing by over 9,200%, reflecting strong market confidence in the future potential of Ivonescimab.
See More
